NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. NanoViricides also noted that NV-387, a broad-spectrum antiviral candidate, has been proposed for evaluation against Ebola virus infections and that the shipment makes the drug locally available should it be utilized in response efforts. The company believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
This development is significant because MPox, particularly the Clade I strain, has been a persistent public health challenge in Central Africa, with limited treatment options. NV-387 is a novel nanoviricide drug candidate designed to target viruses through a unique mechanism. If the Phase II trial proves successful, it could provide a much-needed therapeutic option for MPox and potentially other viral outbreaks. The broad-spectrum nature of NV-387 also opens the door for its use in treating Ebola, a disease with high mortality rates and few approved treatments.
NanoViricides is a clinical stage company focused on creating special purpose nanomaterials for antiviral therapy. The company’s lead drug candidate, NV-387, is being developed for a range of viral infections, including respiratory syncytial virus (RSV), COVID-19, influenza, and MPox. The company also has a drug candidate for shingles, NV-HHV-1, in its pipeline.
For more details on the press release, visit https://ibn.fm/CTIZc. Additional information about NanoViricides can be found on their website at https://www.nanoviricides.com.
